Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vaccine efficacy determination.

C V Broome1

  • 1Science Centers for Disease Control, Atlanta, Georgia.

NIPH Annals
|December 1, 1991
PubMed
Summary
This summary is machine-generated.

Randomized, placebo-controlled, double-blind efficacy trials are the gold standard for vaccine testing. While immunogenicity studies offer insights, efficacy trials are crucial for definitive vaccine performance assessment, especially for rare diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Symposium on Statistical Bases for Public Health Decision Making: From Exploration to Modelling. Introduction and welcome.

Statistics in medicine·1999
Same author

A randomised trial of a Haemophilus influenzae type b conjugate vaccine in a developing country for the prevention of pneumonia--ethical considerations.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·1999
Same author

Effective global response to emerging infectious diseases.

Emerging infectious diseases·1998
Same author

Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland.

The Journal of infectious diseases·1998
Same author

Meningococcal vaccine in sub-Saharan Africa.

Lancet (London, England)·1997
Same author

Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine.

The Journal of infectious diseases·1997
Same journal

Time variations in injury incidence.

NIPH annals·1993
Same journal

Optimalized in vivo production of monoclonal antibodies in mouse ascitic fluid.

NIPH annals·1993
Same journal

Observations on Pseudomonas aeruginosa proteolytic and toxic activity in experimentally infected rats.

NIPH annals·1992
Same journal

Sogn and Fjordane county community-based injury prevention: evaluation design.

NIPH annals·1992
Same journal

Fleas (Siphonaptera) from seabirds and their nests in mainland Norway and Spitzbergen.

NIPH annals·1992
Same journal

Abstracts of the Norwegian Virology Symposium IV. Ustaoset, March 19-20, 1992.

NIPH annals·1992
See all related articles

Area of Science:

  • Vaccinology
  • Clinical Trial Design
  • Epidemiology

Background:

  • Randomized, placebo-controlled, double-blind efficacy trials represent the gold standard in vaccine evaluation.
  • Serologic parameters can assess vaccine performance after a protective immune mechanism is established.
  • Immunogenicity studies provide valuable data, but efficacy trials are often necessary for conclusive results.

Purpose of the Study:

  • To highlight the critical role of efficacy trials in vaccine development.
  • To discuss the challenges and considerations in designing and conducting vaccine efficacy trials.
  • To emphasize maximizing data acquisition from each trial, particularly for rare diseases.

Main Methods:

  • Discussion of key issues in pre-licensure vaccine studies.

Related Experiment Videos

  • Consideration of trial design elements including vaccine and site selection.
  • Examination of group assignment, endpoint surveillance, and surrogate marker identification.

    • Main Results:

    • Efficacy trials are essential for definitive vaccine performance evaluation.
    • Conducting efficacy trials for rare diseases presents significant cost and logistical challenges.
    • Careful planning and execution of trial components are paramount for reliable outcomes.

    Conclusions:

    • Efficacy trials remain indispensable for validating vaccine effectiveness.
    • Optimizing trial design and execution is crucial for overcoming challenges in rare disease vaccine research.
    • Comprehensive evaluation requires meticulous attention to all aspects of study conduct and monitoring.